Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

Next Previous
Trial Profile

A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cretostimogene grenadenorepvec (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use
  • Acronyms CORE-001; CORE1
  • Sponsors CG Oncolgy

    • Most Recent Events

    • 01 May 2023 Results assessing the effect of of Cg0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin presented at the 118th Annual Meeting of the American Urological Association
    • 01 May 2023 According to a CG Oncolgy media release, the company plan to follow the patients in complete remission beyond 12 months to ascertain longer-term response to cretostimogene grenadenorepvec and pembrolizumab.
    • 01 May 2023 According to a CG Oncolgy media release, results from this trial were presented in an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top